Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/5/2025

Management of Tirzepatide After Reaching Goal Weight

Evidence for Continued Therapy

  • The American Diabetes Association recommends continuing weight management medications long-term unless clinical circumstances or other considerations suggest otherwise 1
  • Sudden discontinuation of tirzepatide leads to substantial weight regain, with studies showing 50-67% of weight being regained within one year after stopping the medication 1, 2

Clinical Decision Algorithm

  • For patients who have reached goal weight, the American Diabetes Association suggests continuing tirzepatide at the lowest effective dose that maintains the weight loss 1, 2
  • Schedule follow-up visits at least quarterly to monitor weight maintenance and medication effectiveness, as recommended by the American Diabetes Association 1

Monitoring Recommendations

  • After reaching goal weight, continue monitoring at least quarterly, as recommended by the American Diabetes Association 1
  • Monitor for improvements in comorbid conditions, such as hypertension, dyslipidemia, and glycemic control 4
  • Evaluate the need for adjustment of other medications that may have been prescribed for obesity-related conditions, according to the American Diabetes Association 5

Important Considerations and Pitfalls

  • Discontinuing tirzepatide prematurely after reaching goal weight can lead to significant weight regain, as warned by the American Diabetes Association 1
  • Women of reproductive potential must continue reliable contraception while on tirzepatide, as the medication is contraindicated in pregnancy, according to the American Diabetes Association 6

Special Situations

  • For patients who cannot continue tirzepatide due to side effects or cost, intensify lifestyle interventions and consider alternative weight management approaches, as recommended by the American Diabetes Association 1, 5